Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.

被引：1
|
作者：
Lang, I.
Inbar, M. J.
Greil, R.
Steger, G. G.
Beslija, S.
Kahan, Z.
Eniu, A. E.
Zvirbule, Z.
Sirbu, D. E.
Zielinski, C.
机构：
[1] Natl Inst Oncol, Budapest, Hungary
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] Univ Hosp Salzburg, Salzburg, Austria
[4] Med Univ Vienna, Vienna, Austria
[5] Univ Sarajevo, Inst Oncol, Clin Ctr, Sarajevo 71000, Bosnia & Herceg
[6] Univ Szeged, Szeged, Hungary
[7] Canc Inst I Chiricuta, Cluj Napoca, Romania
[8] Oncol Ctr Latvia, Riga, Latvia
[9] Med Univ Vienna, Dept Med 1, Div Clin Oncol, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1126
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
    Lang, I.
    Inbar, M.
    Steger, G.
    Greil, R.
    Zvirbule, Z.
    Beslija, S.
    Kahan, Z.
    Taskova, V.
    Kaufmann, B.
    Zielinski, C. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
  • [2] SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)
    Lang, I.
    Inbar, M.
    Greil, R.
    Kahan, Z.
    Beslija, S.
    Steger, G. G.
    Stemmer, S. M.
    Zvribule, Z.
    Kaufman, B.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [3] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [4] Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
    Lang, I.
    Inbar, M. J.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G. G.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (17) : 3140 - 3149
  • [5] Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data
    Inbar, M.
    Lang, I.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G. G.
    Zielinski, C. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S346 - S346
  • [6] Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C. C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Zvirbule, Z.
    Steger, G. G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S263 - S264
  • [7] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
    Klare, P.
    Foerster, F. G.
    Geberth, M.
    Schneeweiss, A.
    Tesch, H.
    Kuemmel, S.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    Nota, Nienke M.
    de Groot, Steffen M.
    Jager, Agnes
    Bos, Monique M. E. M.
    Linn, Sabine C.
    van den Bosch, Joan
    Braun, Hans J.
    van der Velden, Ankie M. T.
    Los, Maartje
    Portielje, Johanneke E. A.
    Kroep, Judith R.
    Honkoop, Aafke H.
    Smorenburg, Carolien H.
    Tanis, Bea
    van Riel, Johanna M. G. H.
    Terwogt, Jetske M. Meerum
    den Boer, Marien O.
    Douma, Joep
    Jeurissen, Frank
    Berends, Johan
    van Tinteren, Harm
    Boven, Epie
    CANCER RESEARCH, 2015, 75
  • [9] FIRST EFFICACY RESULTS FROM THE TURANDOT PHASE III TRIAL COMPARING TWO BEVACIZUMAB (BEV)-CONTAINING REGIMENS AS FIRST-LINE THERAPY FOR HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Zielinski, C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 116 - 116
  • [10] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
    Miles, D. W.
    De Haas, S. L.
    Romieu, G.
    Chan, A.
    Dirix, L.
    Cortess, J.
    Delmar, P. R.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S176 - S176
12345